| Literature DB >> 35437325 |
Creg J Workman1,2,3,4, Dario A A Vignali5,6,7,8,9, Clifford Guy10, Diana M Mitrea11,12, Po-Chien Chou10, Jamshid Temirov13, Kate M Vignali10,14,15, Xueyan Liu16,17, Hui Zhang16,18, Richard Kriwacki11,19, Marcel P Bruchez20,21,22, Simon C Watkins23.
Abstract
LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function remains unclear. Here, we show that LAG3 moved to the immunological synapse and associated with the T cell receptor (TCR)-CD3 complex in CD4+ and CD8+ T cells, in the absence of binding to major histocompatibility complex class II-its canonical ligand. Mechanistically, a phylogenetically conserved, acidic, tandem glutamic acid-proline repeat in the LAG3 cytoplasmic tail lowered the pH at the immune synapse and caused dissociation of the tyrosine kinase Lck from the CD4 or CD8 co-receptor, which resulted in a loss of co-receptor-TCR signaling and limited T cell activation. These observations indicated that LAG3 functioned as a signal disruptor in a major histocompatibility complex class II-independent manner, and provide insight into the mechanism of action of LAG3-targeting immunotherapies.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35437325 PMCID: PMC9106921 DOI: 10.1038/s41590-022-01176-4
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 31.250